A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura

Exclusion Criteria

• •All subjects on coumadin, heparin, plavix, supplemental herbs, vitamin E, empirin, fiorinal, norgesic, forte, percodan, robaxin, nuprin, ansaid, anaprox, clinoril, dolobid, feldene, naprosyn, voltaren, fish oil, oral steroids, or daily use of aspirin, Motrin, or Advil. (PRN usage not excluded)
• •Prior treatment with any systemic immunosuppressive therapy including but not limited to chemotherapy agents or corticosteroids within 3 months of study enrollment is prohibited.
• •Clotting abnormalities as determined by screening labs
• •Any history of a stroke or unstable heart disease
• •Participation in another clinical trial with exposure to any investigational agent within 30 days prior to Screening Visit.
• •Any condition the Investigator believes would interfere with subject's ability to provide informed consent, comply with study instruction, or which might confound the interpretation of the study results or put the subject at undue risk.
• •Subject is pregnant, breastfeeding or planning a pregnancy during the study.
• •Subject is unable to communicate or cooperate with the Investigator due to a language barrier (non-English speaking).
• •Subjects who are allergic to adapalene or the ingredients in the gel.